A few limitations exist within this study
GLP-1 medications may be appropriate for adults with: BMI 30 kg/m BMI 27 kg/m with obesity-related conditions such as diabetes, hypertension, sleep apnea, or fatty liver disease Difficulty losing weight despite lifestyle changes Treatment suitability should always be determined by an endocrinologist after a comprehensive evaluation
It doesnt involve clinics, appointments, or injections
The exception is oral semaglutide, marketed as Rybelsus
Other important side effects include gallbladder disease (cholelithiasis, cholecystitis), and potential worsening of diabetic retinopathy (particularly with rapid HbA1c reduction on semaglutide)
To learn more about this report, GLP-1 Receptor Agonist Market Insights, By Route of Administration: Parenteral Contributes the Highest Share of the Market Due to its Convenience By route of administration, the parenteral segment is estimated to contribute the highest market share owing to its unparalleled convenience